Company: KROS
Filing Date: 2025-03-31
Form Type: 8-K
Source: 0001664710-25-000029
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-03-31
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On March 31, 2025, Keros Therapeutics, Inc. (the “ Company”) issued a press release announcing initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

During a conference call and webcast scheduled to be held at 8:00 a. m. Eastern time on March 31, 2025, the Company’s management will discuss the initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. A copy of the presentation for the conference call and webcast is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference.

Item 9.01 Financial Statements and Exhibits.